IMNM
Immunome, Inc.
Stock
$20.90+0.01 (+0.05%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $520M | $653M | $217M | $138M | $20M | $49M | $40M | $2.5M |
| Current assets | $538M | $661M | $221M | $145M | $23M | $57M | $43M | $3.1M |
| Total assets | $565M | $683M | $240M | $149M | $24M | $58M | $45M | $5.1M |
| Current liabilities | $36M | $45M | $54M | $22M | $7.3M | $9.7M | $3.0M | $1.7M |
| Long-term debt | — | — | — | — | — | — | $134K | — |
| Total liabilities | $40M | $49M | $59M | $29M | $7.4M | $9.7M | $3.2M | $1.8M |
| Shareholders' equity | $525M | $634M | $181M | $120M | $17M | $48M | $41M | −$36M |
| Shares outstanding | 113.6M | 113.1M | 87.0M | 59.7M | 12.2M | 12.1M | 10.7M | — |
| Current ratio | 15.08 | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 |